Looking ahead here is our curated list (in order, by date) of the top cardiology conferences planned for 2022. 19th International Conference on Pediatrics and Pediatric Cardiology May 18-19, 2022 Location: Amsterdam, Netherlands & Online The main focus and theme for the Pediatric Cardiology 2022 conference is “Emerging interventions in Pediatric … [Read more...] about Top Cardiology Conferences 2022
Feature
Rivaroxaban plus aspirin confers mortality benefit over aspirin alone
The COMPASS trial (NCT01776424) compared outcomes of subjects with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) taking rivaroxaban plus aspirin with subjects taking aspirin alone. The primary outcome (a composite of myocardial infarction, stroke, or cardiovascular [CV] death) was decreased by 24% in the group taking rivaroxaban plus aspirin. … [Read more...] about Rivaroxaban plus aspirin confers mortality benefit over aspirin alone
Lowering target systolic blood pressure may decrease cardiovascular events
International Society of Hypertension global hypertension guidelines1 and European Society of Cardiology guidelines2 both recommend that hypertension be diagnosed if a patient’s systolic blood pressure is ≥140 mmHg and/or their diastolic blood pressure is ≥90 mmHg. Researchers wondered if pharmaceutical intervention at a lower systolic blood pressure could further reduce the … [Read more...] about Lowering target systolic blood pressure may decrease cardiovascular events
Fractional flow reserve vs angiography-guided revascularization
Fractional flow reserve (FFR) guided revascularization did not demonstrate any benefit over angiography guided revascularization in the FLOWER-MI trial. In patients with ST-elevated myocardial infarction (STEMI) and multi-vessel disease, complete vascularization is associated with better clinical outcomes than vascularization of only the culprit lesion. Current … [Read more...] about Fractional flow reserve vs angiography-guided revascularization
Clopidogrel monotherapy superior to aspirin monotherapy following PCI
In the HOST-EXAM trial investigators found monotherapy with clopidogrel (in patients who had experienced an event-free 6 to 18 months) following percutaneous coronary intervention (PCI; using a drug-eluting stent) was superior to monotherapy with aspirin, over a 2-year follow-up period. Clopidogrel was associated with both fewer thrombotic and bleeding endpoints. In … [Read more...] about Clopidogrel monotherapy superior to aspirin monotherapy following PCI